Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 10/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 4/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29120941 | 0.90 | GRM1 (0.42) | GRM1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL8350087 | 0.81 | GRM1 (0.52) | GRM1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL30632987 | 0.79 | GRM1 (0.55) | GRM1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL29120932 | 0.79 | GRM1 (0.55) | GRM1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL8353952 | 0.78 | GRM1 (0.80) | GRM1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL8350623 | 0.74 | GRM1 (0.45) | GRM1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL26628020 | 0.73 | GRM1 (0.43) | GRM1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL13597817 | 0.72 | GRM1 (0.46) | GRM1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL22575141 | 0.71 | GRM1 (0.34) | GRM1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL29120942 | 0.71 | GRM1 (0.42) | GRM1TP53CYP3A4MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-7902369-B2 | Diaryl-substituted five-membered heterocycle derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7517517-B2 | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-14 | — | — | US | disclosed |
| US-7517517-B2 | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-14 | — | — | US | disclosed |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | MSD K.K. (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1726585-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| WO-2003082350-A2 | RADIOLABELLED QUINOLINE AND QUINOLINONE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | OPRK1, GRM1, GRIK1 | GRM1 2/4885TP53 4814/4885CYP3A4 767/4885 |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | OPRK1, OPRL1, GRM1 | GRM1 3/4885TP53 4576/4885CYP3A4 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.